Jacob Plieth

@JacobPlieth · London, UK · joined 11 Oct 2012

Journalist @ApexOnco. The Wolverine Of Biotech / Mr ASH. Interested in: oncology. Not interested in: what stock you bought today. My internal plan is as follows

33 172Followers

284Following

29 127Posts total

37.1KViews on collected posts

Ultimi post

Jacob Plieth@JacobPlieth14 Sep

Nice Arros-1 vs Trust I/II vs Trident-1 cross-trial comparisons by #WCLC26 discussant Malinda Itchins. Pretty clear $GSK got the better drug (at a price). $NUVB https://t.co/VsJJ5w2MNE

2.8K views · 25 likes · 7 reposts · 2 replies Open on X →

Jacob Plieth@JacobPlieth14 Sep

Meanwhile, $AZN $DSNKY are filing on these data. Sure, why not? #WCLC26 https://t.co/0Xg2UjpZGD

2.8K views · 17 likes · 0 reposts · 1 replies Open on X →

Jacob Plieth@JacobPlieth14 Sep

Here's an important detail from #WCLC26 about Harmoni-2: the positive OS data are from a 2nd interim analysis, conducted at 234 events. Sig threshold was 1-sided alpha of 0.0141 $SMMT https://t.co/eUIxR5VJp1

1.4K views · 2 likes · 0 reposts · 1 replies Open on X →

Jacob Plieth@JacobPlieth13 Sep

@JacobPlieth Still inferior to sac-TMT, correct? 3.7K views · 6 likes · 0 reposts · 6 replies Open on X →

Jacob Plieth@JacobPlieth13 Sep

In Harmoni-2 Keytruda outperformed KN-042, and still $SMMT ivonescimab beat it on OS. Yes, I know KN-042 is 10 years old, and I know these are China data, but still this is good. HR=0.73 beats analyst expectations (~0.77) #WCLC26 https://t.co/Dfiw9kCUDc

12.7K views · 62 likes · 13 reposts · 7 replies Open on X →

Jacob Plieth@JacobPlieth12 Sep

$BNTX $BMY pumitamig + B7-H3 might be better than either agent alone. Via @ByMadeleineA @ApexOnco from #WCLC26 -> https://t.co/SlJ8R1OrBH $SMMT 6.8K views · 30 likes · 7 reposts · 2 replies Open on X →

Jacob Plieth@JacobPlieth9 Sep

First-line accelerated approval for Bayer's Hyrnuo https://t.co/RR7D2rIuuh 6.8K views · 13 likes · 2 reposts · 0 replies Open on X →

Rispetto ad account della stessa dimensione

7 post degli ultimi 90 giorni, accanto alla fascia di 10K–100K follower. arriva a molti, ma pochi di loro reagiscono.

Visualizzazioni mediane3 708questo account955mediana per 10K–100K

Copertura, %11.18%questo account3.50%mediana per 10K–100K

Interazione, %0.57%questo account1.57%mediana per 10K–100K

Metrica	Questo account	Mediana per 10K–100K	Rapporto
Visualizzazioni mediane per post	3 708	955	3.88×
Copertura (visualizzazioni ÷ follower)	11.18%	3.50%	3.19×
Tasso di interazione	0.57%	1.57%	0.37×

Altri account di questa fascia → Confronta con un altro account → Come sono costruiti questi parametri →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

6.8K9 Sep

6.8K12 Sep

12.7K13 Sep

3.7K

1.4K14 Sep

2.8K

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.22%9 Sep

0.58%12 Sep

0.64%13 Sep

0.32%

0.22%14 Sep

0.64%

1.20%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.57%.

What the audience does

Likes59.8%155 in total

Reposts11.2%29 in total

Replies7.3%19 in total

Bookmarks21.6%56 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Ultimi post

Rispetto ad account della stessa dimensione

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Account simili